Abstract library

13 results for "Scales".
#1651 Renal Neuroendocrine Tumors (rNETs): A Single-Center Experience.
Introduction: rNETs are rare tumors and little is known about their natural history.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Non digestive NETs (bronchial, MTC pheochromocytoma) Pathology, grading, staging
Presenting Author: Dr. Thorvardur Halfdanarson
Keywords: Renal, Kidney, NET, Carcinoid
#43 Relationship between neuroendocrine tumor-related symptoms and RAND-36 health-related quality of life scores
Introduction: Neuroendocrine tumors (NETs) can secrete hormones that cause flushing and diarrhea (carcinoid syndrome) and disrupt health-related quality of life (HRQL).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors: Beaumont J L, Liu Z, Choi S, Yao J C, ...
#45 Neuroendocrine tumor disease state and RAND-36 health-related quality of life scores
Introduction: Health-related quality of life (HRQL) can be disrupted in patients with malignancies.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors: Phan A, Beaumont J L, Liu Z, Choi S, ...
#358 Enhanced Combined 177Lu-DOTATATE and 90Y-DOTATATE Treatment of Patients with Metastatic Neuroendocrine Tumors Refractory to Conventional Therapy: An Ongoing Study.
Introduction: Neuroendocrine tumors (NETs) over-express somatostatin receptors (SRs) and the efficacy of peptide receptor radionuclide therapy (PRRT) with somatostatin analogues labeled with high activities of ß-emitting radioisotopes have been reported.
Conference:
Category: Basic
Presenting Author: Dr Andrew Mallia
#452 Clinical and Psychometric Validation of the Disease-Specific Questionnaire Module (EORTC QLQ-GINET21) in Assessing Quality of Life of Patients with Neuroendocrine Tumors
Introduction: Quality of life (QoL) is an important outcome measure in clinical trials and is increasingly being used as an endpoint. The QLQ-GINET21 is a questionnaire developed with the EORTC QoL Group but which had not previously been validated.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr John Ramage
#481 Quality of Life in Patients with Neuroendocrine Tumors: A Cross-Sectional Study
Introduction: Living with cancer affects not only physical and mental health but also the social and professional life of the patient. Measuring quality of life (Qol) is one way to learn from the patient perspective.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MRS Lise Plum
Authors: Plum L, Knigge U, ...
Keywords: quality of life
#1178 Treatment Satisfaction, Symptom Control and Quality of Life (QoL) with Lanreotide Autogel (LAN) in NET Patients with Carcinoid Syndrome (CS): Results from the SYMNET Study
Introduction: CS associated with NETs can have a negative impact on patients’ QoL.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Philippe Ruszniewski
Keywords: quality of life
#1193 Health-Related Quality of Life (HRQoL) with Lanreotide Autogel (LAN) 120 mg in Patients with Enteropancreatic (EP-) NETs: Post Hoc Analyses from the CLARINET Study
Introduction: In CLARINET, favourable efficacy and safety with LAN in metastatic EP-NETs was associated with stable HRQoL outcomes.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Martyn Caplin
Authors: Caplin M, Pavel M, Cwikla J B, Phan A T, ...
#1335 Quality of Life (QoL) and Psycho-social Distress in Patients with Neuroendocrine Neoplasias (NEN) – Correlation with Tumor Stage, Clinical Status and Treatment
Introduction: Pat. with NEN require long-term therapy potentially associated with an impairment of QoL
Conference: 13th Annual ENETS conference 2016 (2016)
Category: ...none of the above
Presenting Author: PD. Dr. Christian Fottner
Authors: Reinhold M, Beutel M, Weber M M, ...
#1856 Relationship Between Symptoms and HRQoL Benefits in Patients (pts) with Carcinoid Syndrome (CS): A Post-Hoc Analysis of Telotristat Ethyl (TE) TELESTAR Trial
Introduction: TELESTAR previously demonstrated the efficacy and safety of TE in pts with CS experiencing >4 Bowel Movements (BM) per day despite stable-dose somatostatin analog therapy. Significantly higher rates of Durable Response (DR, predefined as Bowel Movement (BM) frequency reduction ≥30% from baseline for ≥50% of the 12 week double blind period) were observed with TE (TE 250mg: 44%, TE 500mg: 42%) vs placebo (20%).
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Others
Presenting Author: Florence Marteau